Clinical significance of establishing a red blood cell alloantibody detection database
10.13303/j.cjbt.issn.1004-549x.2025.01.009
- VernacularTitle:建立红细胞同种抗体检测数据库的临床意义
- Author:
Xiao XIAO
1
;
Long CHEN
1
;
Zhenyu ZHAO
1
;
Zhanghan HE
1
;
Mengjun ZHOU
1
;
Jie TANG
1
Author Information
1. Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China
- Publication Type:Journal Article
- Keywords:
antibody screen;
alloantibody;
antibody decay;
antibodies of undetermined specificity (AUS)
- From:
Chinese Journal of Blood Transfusion
2025;38(1):54-60
- CountryChina
- Language:Chinese
-
Abstract:
[Objective] To explore the clinical significance and application value of establishing a database for red blood cell alloantibody detection. [Methods] Patients who were scheduled for blood transfusion in our hospital from January 1, 2020 to May 1, 2024 were selected as the research subjects. A red blood cell alloantibody detection database was established using Microsoft Office Excel software to register the detection data of patients' alloantibodies and antibodies of undetermined specificity (AUS). A retrospective analysis was conducted on the clinical characteristics, antibody distribution, antibody decay and repeat positivity of the patients in the database. The LISS-IAT method was routinely used for antibody screening and identification. [Results] Among the alloantibodies, the Rh blood group system had the highest detection rate, followed by antibodies of the MNS blood group system and the Lewis blood group system. The predominant antibody in the Rh blood group system was anti-E. In the univariate analysis, the positivity of antibody was significantly associated with the patient's gender, age, blood transfusion history, pregnancy history and type of disease (all P<0.001). In the database, 48 patients experienced antibody decay, accounting for 15.24%(48/315), with an average time span of antibody decay ranging from 22 to 1 324 days. Six cases showed repeat positivity after decay, which were related to blood transfusions. The shortest interval between blood transfusions that led to antibody repeat positivity was 3 days, and the longest interval was 427 days. Among 58 cases with AUS, 3 converted into alloantibodies, among which 2 were anti-E and 1 was anti-Lea. [Conclusion] Establishing a red blood cell alloantibody detection database is an effective way to guide ambiguous cross-matching in clinical practice and is also an effective measure for the management of transfusion risks.
